|  |
| --- |
| **Supplemental Table 1.** Risk**a** of ≥CIN3, stratified by HPV genotype in subjects with any cytology result. |
|  | **Monsonego (2015)**GO; BL [[28](#_ENREF_28)] | **Vaughan (2018)**BL [[37](#_ENREF_37)] | **Wheeler (2014)**IJC; 3 yr [[35](#_ENREF_35)] | **Schiffman (2016)**IJC; 3.5 yr [[31](#_ENREF_31)] | **Naucler (2007)**BrJC; 4.1 yr [[29](#_ENREF_29)] | **Kitchener (2014)**HTA-NHS; 6 yr [[26](#_ENREF_26)] | **Smelov (2015)**IJC; 14 yr [[33](#_ENREF_33)] |
| **HPV GT** | 25-29 yrs | ≥30 yrs | ≥25yrs | ≥21 yrs | ≥30 yrs | 32-38 yrs | ≥20 yrs | 32-38 yrs |
| **16** | 14.2 (10.8-18.4) | 15.1 (12.3-18.4) | 14.9 (11.7-19.8) | 8.0 (6.5-9.6) | 21.9 (20.1-23.7) | 28.2 (20.9-36.3) | 30.4 (26.7-34.2) | 34.5 (28.4-41.5) |
| **31** | 8 4. (4.5-13.7) | 7.9 (5.3-11.7) | 9.8 (6.9-13.6) | 3.1 (1.9-4.4) | 8.1 (6.6-9.5) | 22.8 (14.1-33.6) | 15.4 (10.9-20.8) | 28.4 (18.2-42.7) |
| **18** | 2.7 (0.9-7.6) | 9.0 (5.9-13.4) | 5.2 (2.8-9.6) | 2.9 (1.5-4.3) | 11.5 (9.2-13.8) | 15.4 (5.9-30.5) | 11.7 (6.9-18.0) | 29.7 (19.6-43.4) |
| **33** | 15.0 (5.2-36.0) | 5.4 (2.3-12.0) | n/r | 5.2 (1.8-8.6) | n/r | 28.0 (12.1-49.4) | 17.6 (11.4-25.4) | 34.1 (19.2-55.6) |
| **58** | 1.6 (0.3-8.3) | 1.7 (0.6-4.8) | n/r | 1.7 (0.7-2.8) | n/r | 21.7 (7.5-43.7) | 7.4 (2.7-15.3) | 18.3 (9.6-33.3) |
| **33/58** | n/r | n/r | 4.2 (2.4-7.4) | n/r | 8.6 (6.9-10.3) | n/r | n/r | n/r |
| **52** | 6.7 (3.7-11.9) | 4.4 (2.6-7.3) | 3.3 (1.8-5.8) | 1.1 (0.4-1.7) | 5.6 (4.4-6.7) | 13 (2.8-33.6) | 5.2 (2.4-9.6) | 14.0 (8.8-21.8) |
| **45** | 0.0 (0.0-5.9) | 4.3 (2.1-8.7) | 2.6 (1.1-6.0) | 1.3 (0.2-2.4) | 5.4 (3.8-7.0) | 7.7 (2.1-18.5) | 6.6 (2.9-12.6) | 16.0 (10.4-24.2) |
| **35** | 4.3 (1.5-12.0) | 3.5 (1.6-7.4) | n/r | 0.8 (0.1-1.5) | n/r | 4.5 (0.1-22.8) | n/r | 15.6 (6.1-36.9) |
| **39** | 3.3 (1.1-9.2) | 3.5 (1.8-6.7) | n/r | 0.4 (0.1-0.8) | n/r | 11.8 (1.5-36.4) | n/r | 9.1 (3.0-25.8) |
| **68** | n/r | n/r | n/r | 0.2 (0.0-0.6) | n/r | n/r | n/r | 7.1 (1.0-40.9) |
| **35/39/68** | n/r | n/r | 1.5 (0.7-2.8) | n/r | n/r | n/r | n/r | n/r |
| **51** | n/r | n/r | 1.6 (0.5-4.5) | 0.4 (0.0-0.9) | 2.0 (1.5-2.5) | 17.2 (5.8-35.7) | n/r | 7.0 (3.2-14.9) |
| **56** | n/r | n/r | n/r | 0.2 (0.0-0.6) | 2.9 (1.9-3.9) | 2.6 (0.06-13.5) | n/r | 4.6 (1.5-13.6) |
| **59** | n/r | n/r | n/r | 0.6 (0.0-1.1) | n/r | 0 | n/r | 5.6 (1.4-20.5) |
| **66** | n/r | n/r | n/r | n/r | n/r | 3.7 (0.0-19.0) | n/r | 7.1 (1.0-40.9) |
| **56/59/66** | n/r | n/r | 0.2 (0.0-1.2) | n/r | 1.5 (1.0-1.9) | n/r | n/r | n/r |
| **Any HPV pos** | 6.1 (5.0-7.5) | 5.4 (4.7-6.3) | 5.3 (4.6-6.1)b | n/r | n/r | 18.4 (15.0-22.3) |  | 20.7 (17.6-24.2) |
| **HPV neg** | n/r | n/r | 0.2 (0.03-0.45)b | n/r | 0.08 (0.07-0.08) | 0.2 (0.3-0.6) | 0.3 (0.2-0.4) | 0.9 (0.6-1.3) |
| **Abbreviations:** ≥CIN3, cervical intraepithelial neoplasia, grade 3 or worse; BL, baseline; yr, year; HPV, human papillomavirus; GT, genotype; yrs, years; n/r, not reported; neg, negative; pos, positive; GO, Gynecologic Oncology; IJC, International Journal of Cancer; BrJC, British Journal of Cancer; HTA-HNS, Health Technology Assessment-National Institute for Health Research (United Kingdom) |
|  |
| **a**Risk listed as percent value with corresponding lower and upper confidence intervals in parenthesesbThese values were not presented in Vaughan et al., 2018; however, they are from the same BD Onclarity™ US PMA Baseline Study data set as the values presented by Vaughan and colleagues and were communicated by the authors |